CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience.
CGRP antibody
Chronic daily headache
Migraine
Real-world
Therapy
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
20 Sep 2021
20 Sep 2021
Historique:
received:
19
07
2021
accepted:
06
09
2021
entrez:
21
9
2021
pubmed:
22
9
2021
medline:
23
9
2021
Statut:
epublish
Résumé
Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected patients with migraine and chronic daily headache without any headache free days were excluded. Thus, less is known about the effectiveness of CGRP antibody treatment in this cohort. Clinical routine data of 32 patients with migraine and daily headache were analysed after three months of treatment with a CGRP antibody (16 erenumab, 7 galcanezumab, 9 fremanezumab), including changes of monthly headache days (MHD) monthly migraine days (MMD) and monthly acute medication intake (AMD) as well as migraine characteristics. Statistical analysis was performed with the Wilcoxon-Test. Migraine characteristics were analysed descriptively. The number of MHD was significantly reduced (mean reduction (standard error), p-value): (-4.2 (1.3), p = 0.009) as well as MMD (-4.3 (1.6), p = 0.033). Four patients (13 %) reached a 50 % reduction regarding MHD and 8 patients (25 %) regarding MMD, migraine duration and intensity improved under therapy. Despite the low responder rate, CGRP antibodies can be effective at least in a few cases of severely affected patients with drug resistant migraine and chronic daily headache. Retrospective registered.
Sections du résumé
BACKGROUND
BACKGROUND
Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected patients with migraine and chronic daily headache without any headache free days were excluded. Thus, less is known about the effectiveness of CGRP antibody treatment in this cohort.
METHODS
METHODS
Clinical routine data of 32 patients with migraine and daily headache were analysed after three months of treatment with a CGRP antibody (16 erenumab, 7 galcanezumab, 9 fremanezumab), including changes of monthly headache days (MHD) monthly migraine days (MMD) and monthly acute medication intake (AMD) as well as migraine characteristics. Statistical analysis was performed with the Wilcoxon-Test. Migraine characteristics were analysed descriptively.
RESULTS
RESULTS
The number of MHD was significantly reduced (mean reduction (standard error), p-value): (-4.2 (1.3), p = 0.009) as well as MMD (-4.3 (1.6), p = 0.033). Four patients (13 %) reached a 50 % reduction regarding MHD and 8 patients (25 %) regarding MMD, migraine duration and intensity improved under therapy.
CONCLUSIONS
CONCLUSIONS
Despite the low responder rate, CGRP antibodies can be effective at least in a few cases of severely affected patients with drug resistant migraine and chronic daily headache.
TRIAL REGISTRATION
BACKGROUND
Retrospective registered.
Identifiants
pubmed: 34544359
doi: 10.1186/s10194-021-01323-6
pii: 10.1186/s10194-021-01323-6
pmc: PMC8454157
doi:
Substances chimiques
Calcitonin Gene-Related Peptide Receptor Antagonists
0
Pharmaceutical Preparations
0
Calcitonin
9007-12-9
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111Informations de copyright
© 2021. The Author(s).
Références
Headache. 2011 Jan;51(1):33-51
pubmed: 21070231
J Headache Pain. 2020 Jul 3;21(1):84
pubmed: 32620151
Headache. 2005 Apr;45(4):315-24
pubmed: 15836567
Lancet Neurol. 2017 Jun;16(6):425-434
pubmed: 28460892
Cephalalgia. 2019 Jul;39(8):931-944
pubmed: 31104507
Neurology. 2020 Nov 3;95(18):e2487-e2499
pubmed: 32913018
Neurology. 2018 Dec 11;91(24):e2211-e2221
pubmed: 30446596
Curr Opin Neurol. 2002 Jun;15(3):287-95
pubmed: 12045727
N Engl J Med. 2017 Nov 30;377(22):2113-2122
pubmed: 29171818
J Am Osteopath Assoc. 2005 Apr;105(4 Suppl 2):23S-29S
pubmed: 15928350
J Headache Pain. 2020 Apr 7;21(1):32
pubmed: 32264820
BMC Neurol. 2018 Nov 9;18(1):188
pubmed: 30413151